News | Biopsy Systems | July 17, 2017

System combines MRI, computer modeling and live ultrasound for faster, more accurate prostate cancer diagnosis after suspicious findings

Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis

July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical imaging and subspecialty radiology to provide better patient care for men with suspicious prostate cancer findings.

The American Cancer Society reports that prostate cancer is the most common cancer and second leading cause of death among U.S. men. Therefore, when positive digital rectal exams (DRE) and elevated PSA (prostate-specific antigen) levels raise suspicion of cancer, a sampling (biopsy) of prostate gland tissue is recommended. These tissue samples are used to help diagnose and determine the grade, or Gleason score, of prostate cancer.

Unfortunately, current biopsy methods are not always efficient at finding actual cancer, leading to repeat and sometimes unnecessary biopsies. That’s where magnetic resonance imaging (MRI) and the UroNav Fusion Biopsy System come in.

“The UroNav approach tends to find those lesions that are more likely to become cancer and require treatment,” said SRA radiologist Larry Schock, M.D., specializing in body imaging and diagnostic radiology. “Radiologists appreciate the computer-aided 3-D imaging capabilities supporting UroNav that improve diagnosis, detection and treatment planning; our male patients appreciate a quicker, more certain diagnosis with fewer repeat or unnecessary biopsies. It’s also an excellent tool for diagnosing high-risk or aggressive prostate cancers.”

If a suspicious lesion is identified using prostate MRI, the UroNav DynaCAD workstation allows SRA radiologists to quickly view and work with 3-D images of the prostate for highly accurate diagnosis and location of suspicious tissue. Urologists then use live ultrasound plus existing 3-D MRI images during biopsy to obtain the best tissue samples.

Before UroNav, physicians relied primarily upon transrectal ultrasound (TRUS) to visualize the prostate gland and sample multiple areas of the prostate in an effort to detect possible cancer cells. However, with TRUS biopsies, cancer can often go undetected, according to recent published research.

“With UroNav, radiologists and urologists work in tandem, using the power of MRI, radiology subspecialty expertise and ultrasound guidance to accurately detect cancer 90 percent of the time,” said Schock. “This combined technology offers a truly new biopsy option for patients with suspicious prostate findings or who are under active surveillance.”

UroNav incorporates prostate image information from pre-biopsy MRI, computer-aided image enhancement and ultrasound-guided needle biopsy. This “fusion” of MRI and ultrasound results in targeted biopsies that are much better at detecting true cancer while avoiding the detection of low-risk or slow-growing cancer.

“Prostate is one of the most common but most curable cancers in men, and early, accurate detection can make all the difference in surviving,” said SRA President Walid Adham, M.D. “It’s incredibly rewarding for our radiology team to work with this advanced UroNav system to improve diagnosis, decrease worry and provide the best care possible to our patients.”

The UroNav fusion biopsy is an outpatient procedure that takes about 15 to 20 minutes and can be performed very shortly after the diagnostic MRI.

UroNav is recommended for patients with a PI-RADS (Prostate Imaging-Reporting and Data System) score of 3 or higher, negative prior TRUS biopsies with a continued elevated or rising PSA, or positive digital rectal examination with a negative TRUS biopsy.

For more information: www.invivocorp.com

Related Content

News | Magnetic Resonance Imaging (MRI)

November 24, 2021 — Royal Philips announced new AI-enabled innovations in MR imaging launching at the Radiological ...

Time November 24, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 22, 2021 — Adolescents and young adults with post-concussive symptoms who suffered three to five concussions ...

Time November 22, 2021
arrow
News | Ultrasound Imaging

November 18, 2021 — Royal Philips, a leader in health technology, announced it has received 510(k) clearance from the U ...

Time November 18, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 17, 2021 — The University of Michigan Health System recently became the first U.S. healthcare institution to ...

Time November 17, 2021
arrow
News | Prostate Cancer

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Videos | Radiation Oncology

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
Videos | Radiation Therapy

Siemens and Philips demonstrated examples of new imaging software to convert MRI datasets into synthetic computed ...

Time November 15, 2021
arrow
News | Radiology Imaging

Noveember 11, 2021 — Siemens Healthineers and UC San Francisco have formed a research and innovation-driven ...

Time November 11, 2021
arrow
Subscribe Now